Edwards Lifesciences “announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability. Edwards’ SAPIEN 3 Ultra RESILIA valve recently received CE Mark for use in patients with heart valve disease due to native calcific aortic stenosis at all levels of surgical risk or due to the failure of either a transcatheter or a surgical bioprosthetic valve who are judged to be at high or greater risk for open surgical therapy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $101 from $100 at Barclays
- Edwards Lifesciences price target lowered to $85 from $86 at Canaccord
- Edwards Lifesciences price target raised to $95 from $92 at UBS
- Edwards Lifesciences backs FY24 EPS view $2.70-$2.80, consensus $2.75
- Edwards Lifesciences sees Q2 adjusted EPS 67c-71c, consensus 70c